Rectal Cancer
Conditions
Keywords
high dose radiotherapy, rectal cancer
Brief summary
While surgery remains the standard treatment for rectal cancer, some patients still firmly refuse surgery for various reasons. Here, we conducted this retrospective observation study to discuss the feasibility of high-dose radiotherapy combined with chemotherapy in treating rectal cancer We retrospectively collect data of rectal cancer patients who were treated with high-dose radiotherapy plus chemotherapy in Sun Yat-sen University Cancer Center from April 1st, 2006 to July 30th, 2017. Patients gave up surgery before any treatment would have received one course of high dose radiotherapy (GTV60-70Gy/30-35f). Patients with tumor residual after neoadjuvant chemoradiotherapy but insisted non-operative treatment would have received 2 courses of radiotherapy (1st: GTV 45-50Gy/25f, 2nd: GTV 30/15f). The chemotherapy regimens included Capox, FOLFOX, or capecitabine at the discretion of the treating physician. After treatment, patients were followed every 3 months for the first two years, at least every 6 months in the year thereafter. Recurrence, early and late toxicity were recorded. Analyses were performed using SPSS software, version 19.0 (SPSS, Chicago, IL). Local recurrence and distant metastasis rate, progression free survival, and overall survival were calculated using the Kaplan Meier Method and were compared by log-rank test.
Interventions
None listed
Sponsors
Sun Yat-sen University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. pathologically confirmed diagnosis of rectal adenocarcinoma located within 15cm from the anal verge; 2. pelvic radiation with a total dose ≥60Gy for the treatment of rectal cancer; 3. refused surgery as the initial treatment; 4. a complete set of clinical information and follow-up data.
Exclusion criteria
1. patients with terminal cancer who received palliative treatment; 2. patients received any treatment before admission to Sun Yat-sen University Cancer Center; 3. patients with second primary cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical response rate | evaluate 5 weeks after radiotherapy | the rate of clinical response in the whole group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| short term and long term side effects | from the complete to 3 years after treatment | short term and long term toxicity related to high dose radiotherapy |
| progression free survival | 3 years | defined as the time from the date of trial entry until disease progression, relapse, or death from any cause. |
| overall survival | 3 years | calculated from the date of trial entry until death from any cause or was censored at last follow-up |
Countries
China
Outcome results
None listed